BDTX RSI Chart
Last 7 days
-20.3%
Last 30 days
-14.6%
Last 90 days
-9.0%
Trailing 12 Months
200.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 2.3M | 0 | 0 | 1.9M |
2022 | 2.7M | 0 | 2.3M | 2.2M |
2021 | 4.4M | 4.5M | 4.1M | 3.5M |
2020 | 1.2M | 2.1M | 3.2M | 4.0M |
2019 | 0 | 0 | 0 | 461.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 15, 2024 | behbahani ali | acquired | 14,373 | 4.54 | 3,166 | - |
Mar 15, 2024 | dixon wendy l | acquired | 14,768 | 4.54 | 3,253 | - |
Dec 15, 2023 | behbahani ali | acquired | 12,162 | 2.73 | 4,455 | - |
Dec 15, 2023 | dixon wendy l | acquired | 11,037 | 2.73 | 4,043 | - |
Oct 17, 2023 | biotech growth n v | bought | 934,080 | 2.3352 | 400,000 | - |
Sep 15, 2023 | velleca mark a. | acquired | 18,748 | 3.6 | 5,208 | president & ceo |
Sep 15, 2023 | behbahani ali | acquired | 11,876 | 3.6 | 3,299 | - |
Sep 15, 2023 | dixon wendy l | acquired | 10,749 | 3.6 | 2,986 | - |
Jul 05, 2023 | ra capital management, l.p. | bought | 4,679,250 | 5.00 | 935,850 | - |
Jul 05, 2023 | behbahani ali | bought | 5,000,000 | 5.00 | 1,000,000 | - |
Which funds bought or sold BDTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | reduced | -48.86 | -445,159 | 5,305,840 | 0.14% |
May 17, 2024 | Ikarian Capital, LLC | sold off | -100 | -1,561,160 | - | -% |
May 16, 2024 | Beacon Capital Management, LLC | unchanged | - | 34,353 | 79,168 | 0.02% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 353 | 1,115,000 | 1,270,310 | -% |
May 15, 2024 | 683 Capital Management, LLC | sold off | -100 | -197,765 | - | -% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | reduced | -11.09 | 3,061,230 | 8,128,220 | 0.85% |
May 15, 2024 | Parkman Healthcare Partners LLC | sold off | -100 | -712,945 | - | -% |
May 15, 2024 | OCCUDO QUANTITATIVE STRATEGIES LP | reduced | -39.16 | 4,975 | 55,932 | 0.01% |
May 15, 2024 | TWO SIGMA ADVISERS, LP | reduced | -6.41 | 199,092 | 488,241 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 348 | 2,427,140 | 2,769,420 | -% |
Unveiling Black Diamond Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Black Diamond Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Black Diamond Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 1.2% | 637 | 630 | 622 | 677 | 562 | 406 | 588 | 776 | 948 | 1,152 | 1,254 | 1,162 | 881 | 744 | 440 | 1.00 | 9.00 | 11.00 |
Operating Expenses | -2.9% | 20,246 | 20,855 | 21,561 | 21,852 | 22,124 | 25,679 | 26,080 | 35,364 | 34,715 | 30,713 | 23,183 | 18,480 | 15,028 | 12,879 | 10,344 | 8,148 | 6,999 | 3,841 |
S&GA Expenses | -100.0% | - | 5,566 | 6,808 | 7,243 | 6,277 | 7,893 | 6,416 | 7,738 | 7,996 | 7,893 | 5,427 | 5,551 | 4,858 | 5,525 | 2,884 | 2,514 | 1,353 | 828 |
R&D Expenses | -11.4% | 13,545 | 15,289 | 14,753 | 14,609 | 15,847 | 17,786 | 19,664 | 27,626 | 26,719 | 22,820 | 17,756 | 12,929 | 10,170 | 7,354 | 7,460 | 5,634 | 5,646 | 3,013 |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 | - | - | - | - | - |
Net Income | 6.1% | -18,225 | -19,408 | -20,875 | -21,078 | -21,654 | -25,507 | -25,867 | -35,077 | -34,351 | -30,301 | -22,626 | -17,912 | -14,571 | -12,145 | -9,875 | -9,268 | -12,287 | -3,828 |
Net Income Margin | 3.2% | -41.47* | -42.85* | -38.17* | -40.83* | -41.15* | -44.45* | -36.26* | -29.63* | -23.29* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -51.9% | -21,199 | -13,956 | -20,031 | -21,939 | -16,468 | -28,607 | -24,379 | -27,971 | -26,013 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Assets | -10.1% | 143 | 159 | 172 | 120 | 136 | 156 | 180 | 199 | 219 | 248 | 274 | 288 | 313 | 330 | 346 | 349 | 363 | 158 | 52.00 |
Current Assets | -11.4% | 119 | 134 | 147 | 93.00 | 108 | 128 | 151 | 169 | 188 | 216 | 242 | 271 | 297 | 320 | 336 | 208 | 362 | 156 | 52.00 |
Cash Equivalents | -53.3% | 26.00 | 56.00 | 58.00 | 42.00 | 39.00 | 34.00 | 54.00 | 56.00 | 54.00 | 67.00 | 47.00 | 37.00 | 14.00 | 36.00 | 56.00 | 64.00 | 357 | 155 | 52.00 |
Net PPE | -5.0% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -8.6% | 38.00 | 42.00 | 38.00 | 38.00 | 37.00 | 41.00 | 47.00 | 46.00 | 47.00 | 52.00 | 55.00 | 37.00 | 33.00 | 22.00 | 19.00 | 6.00 | 8.00 | 5.00 | 7.00 |
Current Liabilities | -14.2% | 17.00 | 20.00 | 15.00 | 14.00 | 13.00 | 15.00 | 21.00 | 20.00 | 19.00 | 24.00 | 26.00 | 23.00 | 19.00 | 14.00 | 11.00 | 6.00 | 7.00 | 5.00 | 3.00 |
Shareholder's Equity | -10.6% | 104 | 117 | 134 | 82.00 | 98.00 | 116 | 133 | 152 | 173 | 196 | 219 | 251 | 281 | 308 | 327 | 343 | 355 | - | - |
Retained Earnings | -4.4% | -435 | -417 | -398 | -375 | -355 | -334 | -313 | -292 | -269 | -243 | -217 | -182 | -148 | -118 | -95.60 | -77.69 | -63.11 | -50.97 | -15.71 |
Additional Paid-In Capital | 1.1% | 540 | 534 | 533 | 458 | 455 | 453 | 450 | 447 | 444 | 440 | 437 | 434 | 429 | 425 | 422 | 420 | 418 | 4.00 | 0.00 |
Shares Outstanding | 1.7% | 53.00 | 52.00 | 52.00 | 37.00 | 37.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 115 | - | - | - | 55.00 | - | - | - | 340 | - | - | - | 1,010 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -51.9% | -21,199 | -13,956 | -18,362 | -14,368 | -20,031 | -21,939 | -16,476 | -18,067 | -28,600 | -24,046 | -26,482 | -25,165 | -24,455 | -15,774 | -11,486 | -13,567 | -11,319 | -7,486 | -5,310 | -5,000 | -6,878 |
Share Based Compensation | 11.5% | 1,713 | 1,536 | 2,751 | 2,646 | 2,671 | 2,906 | 2,664 | 3,252 | 3,375 | 3,376 | 3,009 | 4,558 | 3,094 | 2,470 | 1,999 | 1,419 | 1,877 | 2,510 | 850 | 192 | 91.00 |
Cashflow From Investing | -212.1% | -13,734 | 12,249 | -37,884 | 17,175 | 24,806 | 2,322 | 14,507 | 19,808 | 16,729 | 43,242 | 35,697 | 48,200 | 3,474 | -6,648 | 4,597 | -279,640 | - | -2.00 | -11.00 | 2.00 | -10.00 |
Cashflow From Financing | 9078.3% | 4,130 | -46.00 | 71,927 | - | 51.00 | -28.00 | 52.00 | - | 153 | - | 64.00 | 184 | 481 | 830 | 270 | - | 213,844 | 83,495 | 44,331 | -70.00 | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 13,545 | $ 14,753 |
General and administrative | 6,701 | 6,808 |
Total operating expenses | 20,246 | 21,561 |
Loss from operations | (20,246) | (21,561) |
Other income (expense): | ||
Interest income | 637 | 622 |
Other income (expense) | 1,384 | 64 |
Total other income (expense), net | 2,021 | 686 |
Net loss | $ (18,225) | $ (20,875) |
Net loss per share, basic (in dollars per share) | $ (0.35) | $ (0.57) |
Net loss per share, diluted (in dollars per share) | $ (0.35) | $ (0.57) |
Weighted average common shares outstanding, basic (in shares) | 51,808,849 | 36,483,878 |
Weighted average common shares outstanding, diluted (in shares) | 51,808,849 | 36,483,878 |
Comprehensive loss: | ||
Net loss | $ (18,225) | $ (20,875) |
Other comprehensive income (loss): | ||
Unrealized gain (loss) on investments, net | (68) | 648 |
Comprehensive loss | $ (18,293) | $ (20,227) |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 25,422 | $ 56,221 |
Investments | 89,777 | 75,179 |
Prepaid expenses and other current assets | 3,607 | 2,634 |
Total current assets | 118,806 | 134,034 |
Property and equipment, net | 1,644 | 1,730 |
Restricted cash | 819 | 823 |
Right-of-use assets | 21,252 | 21,980 |
Total assets | 142,521 | 158,567 |
Current liabilities: | ||
Accounts payable | 1,176 | 2,324 |
Accrued expenses and other current liabilities | 15,678 | 17,322 |
Total current liabilities | 16,854 | 19,646 |
Non-current operating lease liabilities | 21,361 | 22,185 |
Total liabilities | 38,215 | 41,831 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock; $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 52,527,626 shares issued and outstanding at March 31, 2024 and 51,645,557 shares issued and outstanding at December 31, 2023 | 7 | 7 |
Additional paid-in capital | 540,050 | 534,187 |
Accumulated other comprehensive loss | (95) | (27) |
Accumulated deficit | (435,656) | (417,431) |
Total stockholders' equity | 104,306 | 116,736 |
Total liabilities and stockholders' equity | $ 142,521 | $ 158,567 |